| Filed | Form | Description | |
|---|---|---|---|
| 4/28/25 | DEF 14A | DEF 14A | → |
| 4/16/25 | PRE 14A | PRE 14A | → |
| 4/8/24 | DEF 14A | DEF 14A | → |
| 3/28/24 | PRE 14A | PRE 14A | → |
| 4/19/23 | DEF 14A | DEF 14A | → |
| 4/28/22 | DEF 14A | DEF 14A | → |
| Filed | Form | Description | |
|---|---|---|---|
| 3/13/26 | 4 | 4 | → |
| 3/13/26 | 4 | 4 | → |
| 3/3/26 | 4 | 4 | → |
| 2/3/26 | 4 | 4 | → |
| 10/31/25 | 4 | 4 | → |
| 10/31/25 | 3 | FORM 3 | → |
| ↓ | |||
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin (COMP360), is currently in phase 3 clinical trials for treatment-resistant depression.